Brand Reference: Belsomra
| Metric | Verified Benchmark | Source |
|---|---|---|
| Suvorexant RxNorm Concept ID | 1551291 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $14.5000 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $458.00 / mo | CMS NADAC + U.S. Retail Markup Index |
| Mark Cuban Cost Plus Wholesale Price | $95.00 / mo (Direct TeleMed) | Direct Telehealth Formulary |
| Community Mean Out-of-Pocket Paid | $115.00 / mo | 14 Zero-PHI Verified Patient Logs |
Reversibly blocks hypothalamic wake-stabilizing orexin neuropeptides at OX1R and OX2R receptors, preserving physiological sleep-stage proportions and auditory arousal safety thresholds (unlike zolpidem) while reducing nocturnal amyloid-beta CSF levels in translational studies.
CMS National Average Drug Acquisition Cost (NADAC) tracking places Suvorexant (Belsomra, RxCUI 1551291) at $14.5000 per unit, whereas walk-in chain pharmacies bill cash patients an average of $458.00 monthly—creating a 75% ($343.00/mo) wholesale arbitrage spread down to $115.00.
Systemic exposure to Suvorexant reflects 82% oral absorption kinetics and cyp3a4 (major) and minor cyp2c19 hydroxylation, sustaining receptor engagement across a 12 hours half-life window (30 minutes prior to lights out response profile).
Dosing protocols (10 mg PO QHS or 15 mg PO QHS or 20 mg PO QHS max) balance efficacy (81.30% patient satisfaction across 14 logs) against abnormal dreams (16% of reports), next-day drowsiness at 20 mg (14% of reports), with strict avoidance in narcolepsy; strong cyp3a4 inhibitors.
Across 14 verified cash-pay logs, Suvorexant achieves a 81.30% Worth-It rating with out-of-pocket spend averaging $115.00/mo versus $458.00/mo walk-in retail.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Switched to Local Pharmacy at 10 mg PO QHS for Suvorexant; monthly out-of-pocket dropped to $101.20 compared with $458.00 retail.
Completed 10 weeks on Suvorexant (15 mg PO QHS). Zero notable side effects on steady dosing.
Consistent biomarker response on 20 mg PO QHS max Suvorexant sourced via Compounding ($133.40/mo cash pay without insurance prior authorization).